Research supported by the Spanish Association Against Cancer (AECC) has demonstrated that a novel triple drug combination enhances the efficacy of immunotherapy in animal models of several cancer types, including solid tumors of the lung, breast, melanoma, and glioblastoma.
This combination not only acts directly on the tumor but also boosts the immune system’s activity, thereby reducing tumor growth and prolonging overall survival in animal models.
Congratulations to the team led by Dr. Ruben Pio (project lead at Cima Universidad de Navarra-Cancer Center Clínica Universidad de Navarra, CIMA-CCUN), and to Drs. Fernando Lecanda and Felipe Prosper, who also contributed to the study.
